Medigen Biotechnology Corp.
3176
Rank in Stocks
#18278
Medigen Biotechnology Corp. is a Taiwanese biopharmaceutical company dedicated... Medigen Biotechnology Corp. is a Taiwanese biopharmaceutical company dedicated to inventing therapies for liver diseases and various forms of cancer. Its product portfolio includes advanced cell therapies like MAGICELL-NK, which leverages natural killer cells, and MAGICELL-GDT, a T-cell-based treatment. A significant pipeline asset for Medigen is OBP-301. This therapeutic has completed Phase I clinical trials for combination therapy in esophageal cancer in Japan. It is currently being evaluated in ongoing Phase I trials in Japan, combining it with immune checkpoint inhibitors (ICIs) for esophageal cancer, and has advanced to Phase II studies in the United States, investigating its use with ICIs for both esophageal and gastric cancer. Established in 1999, Medigen Biotechnology Corp. maintains its corporate headquarters in Taipei, Taiwan.
Share Price
$0.99379335
Last synced: 2026-11-10
Market Cap
$138.44M
Change (1 day)
0.46%
Change (1 year)
3.53%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Medigen Biotechnology Corp. (3176)
Category
Healthcare
EPS for Medigen Biotechnology Corp. (3176)
EPS as of June 2026 TTM: $-0.06
According to Medigen Biotechnology Corp.'s latest financial reports, its current EPS (TTM) is $-0.06. At the end of 2025 the company had an EPS of $-0.02, an increase over its 2024 EPS of $-0.04.
EPS history for Medigen Biotechnology Corp. from 2016 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.06 | 181.00% |
| 2025 | $-0.02 | -44.42% |
| 2024 | $-0.04 | -65.88% |
| 2023 | $-0.13 | -17.16% |
| 2022 | $-0.16 | 1,056.93% |
| 2021 | $-0.01 | -84.16% |
| 2020 | $-0.09 | 40.65% |
| 2019 | $-0.06 | -41.04% |
| 2018 | $-0.10 | -8.19% |
| 2017 | $-0.11 | -10.13% |
| 2016 | $-0.13 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -27,964.77% |
US
|
|
| $-7.07 | 12,480.07% |
US
|
|
| $-5.29 | 9,312.81% |
AU
|
|
| $12.88 | -23,018.33% |
BE
|
|
| $21.56 | -38,462.99% |
NL
|
Questions about Medigen Biotechnology Corp.'s earnings per share (EPS)
What is Medigen Biotechnology Corp.'s earnings per share (EPS)?
Medigen Biotechnology Corp.'s earnings per share (EPS) over the last twelve months is $-0.06, as of Jun 2026.
What was Medigen Biotechnology Corp.'s earnings per share (EPS) in 2025?
In 2025, Medigen Biotechnology Corp.'s earnings per share (EPS) was $-0.02, compared with $-0.04 in 2024.
How has Medigen Biotechnology Corp.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Medigen Biotechnology Corp.'s earnings per share (EPS) was highest in 2021 ($-0.01) and lowest in 2022 ($-0.16).
How does Medigen Biotechnology Corp.'s earnings per share (EPS) compare with similar companies?
Medigen Biotechnology Corp.'s earnings per share (EPS) ($-0.06) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.